Genmab A/S (GMAB) vs Roivant Sciences (ROIV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Roivant Sciences (ROIV) has outperformed Genmab A/S (GMAB) over the past year, gaining 115.6% versus a gain of 12.3%. Over five years, ROIV leads with a +477.2% price change compared with -17.5% for GMAB. Roivant Sciences is the larger company by market cap ($24.75 billion vs $22.25 billion), about 1.1 times the size, while Genmab A/S is growing revenue faster (+19.2% vs -71.6%).
Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | ROIV |
|---|---|---|
| Share price | $36.18 | $34.26 |
| Market cap | $22.25B | $24.75B |
| 1-day change | -1.28% | -1.41% |
| YTD return | +18.99% | +60.14% |
| 1-year return | +12.29% | +115.57% |
| 5-year return | -17.51% | +477.24% |
| P/E ratio (TTM) | 28.49 | — |
| Forward P/E | 23.72 | — |
| EPS (TTM) | $1.27 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $8.26M |
| Revenue growth (YoY) | +19.19% | -71.57% |
| Net income (latest FY) | $963.00M | $-299.77M |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | -6235.69% |
| Net margin | 25.89% | -3629.19% |
| 52-week high | $40.17 | $42.50 |
| 52-week low | $23.62 | $15.90 |
| Distance from 52-week high | -9.93% | -19.39% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +19.46% | +40.34% |
| Average volume | 2.80M | 7.02M |
| Shares outstanding | 614.90M | 722.32M |
| Employees | 3,119 | 721 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed GMAB by 103.3 percentage points over the past year.
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs -71.57%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
GMAB vs ROIV FAQ
Which is bigger, Genmab A/S or Roivant Sciences?
Roivant Sciences (ROIV) is larger, with a market capitalization of $24.75B compared with $22.25B for Genmab A/S (GMAB).
Which stock has performed better over the past year, GMAB or ROIV?
ROIV returned +115.57% over the past 12 months, compared with +12.29% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Are Genmab A/S and Roivant Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.